阿斯利康AstraZeneca plc (AZN) 2005年年度报告「LSE」.pdf

1、AstraZeneca Annual Report and Form 20-F Information 2005DRIVINGPROGRESSTHROUGHPERFORMANCEAnnual Report and Form 20-F Information 20052005 in Brief1Chairmans Statement2Chief Executives Review3Financial Highlights5Business Review6Business Environment7Strategy9Delivering Strategy10Measuring Performance

2、12Reporting Performance13Therapy Area ReviewCardiovascular Medicines14Gastrointestinal Medicines18Neuroscience Medicines21Oncology Medicines24Respiratory and Inflammation Medicines27Infection Medicines30Geographic Review31Research and Development34Development Pipeline36Commercialisation and Portfoli

3、o Management38Supply39Managing Risk40Corporate Responsibility41Main Facilities43Other Businesses43Industry Regulation43Financial Review45Board of Directors60Directors Report62Audit Committees Report68Directors Remuneration Report70Trade marksTrade marks of the AstraZeneca group of companiesappear th

4、roughout this document in italics.AstraZeneca,the AstraZeneca logotype and the AstraZeneca symbolare all trade marks of the AstraZeneca group of companies.Use of termsIn this Annual Report and Form 20-F Information 2005,unless the context otherwise requires,AstraZeneca,the Group,the Company,we,us an

5、d our refer to AstraZeneca PLC and its consolidated entities.Statements of competitive positionExcept as otherwise stated,market information in thisAnnual Report and Form 20-F Information 2005 regardingthe position of our business or products relative to its ortheir competition is based upon publish

6、ed statistical datafor the 12 months ended 30 September 2005,obtainedfrom IMS Health,a leading supplier of statistical data tothe pharmaceutical industry.Except as otherwise stated,these market share and industry data from IMS Healthhave been derived by comparing our sales revenue tocompetitors and